Helix BioPharma Corp. (T:HBP)

Business Focus: Biotechnology & Medical Research (NEC)

Get the company report for the most recent outlook updated daily

Apr 01, 2024 09:11 am ET

Canadian Investment Regulatory Organization Trade Resumption - HBP

TORONTO, April 1, 2024 /CNW/ - Trading resumes in:

Mar 28, 2024 05:14 pm ET

Canadian Investment Regulatory Organization Trading Halt - HBP

TORONTO, March 28, 2024 /CNW/ - The following issues have been halted by CIRO:

Jan 18, 2024 01:35 pm ET

Helix BioPharma Corp. Reports Voting Results

January 18, 2024 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced the voting results of the Company’s annual and general meeting of shareholders held on January 18, 2024 (the “Meeting”).

Dec 14, 2023 03:00 pm ET

Helix BioPharma Corp. Announces Fiscal 2024 First Quarter Results

Toronto, Ontario – TheNewswire – December 14, 2023 – Helix BioPharma Corp. (TSX:HBP), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the fiscal 2024 first quarter results for the period ending October 31, 2023.

Oct 27, 2023 03:30 pm ET

Helix Biopharma Corp. Announces Fiscal 2023 Year-End Results

Toronto, Ontario - TheNewswire - October 27, 2023 - Helix BioPharma Corp. (TSX:HBP), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the 2023 fiscal year ended July 31, 2023.

Oct 10, 2023 05:00 am ET

Helix Biopharma Announces Upcoming Poster Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Toronto, Ontario - TheNewswire - October 10, 2023 - Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), an immune-oncology antibody-drug-conjugate company developing an innovative drug platform for the treatment of cancer, announced today that the Company will present new preclinical data on L-DOS47 in combination with PD1 checkpoint inhibition at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in the Hynes Convention Center, Boston, via in person attendance, October 11-15, 2023.

Aug 22, 2023 05:00 am ET

Helix BioPharma Corp. Announces Closing of Private Placement of CAD $3 Million and Board Changes

Toronto, Ontario - TheNewswire - August 22, 2023 - Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announces that it has closed the first tranche of private placement financing for gross proceeds of CAD $2,998,000 from the issuance of 16,655,557 common shares at a price of $0.18 per common share.

Jun 14, 2023 03:00 pm ET

Helix BioPharma Corp. Announces Fiscal 2023 Third Quarter Results

Toronto, Ontario – TheNewswire – June 14, 2023 - Helix BioPharma Corp. (TSX:HBP), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the fiscal 2023 third quarter results for the period ending April 30, 2023.

Mar 15, 2023 03:00 pm ET

Helix Biopharma Corp. Announces Fiscal 2023 Second Quarter Results

Toronto, ON - TheNewswire - March 15, 2023 - Helix BioPharma Corp. (TSX:HBP), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the fiscal 2023 second quarter results for the period ending January 31, 2023.

Jan 24, 2023 10:15 am ET

Helix Biopharma Corp. Reports Voting Results

Toronto, Ontario – TheNewswire – January 24, 2023 - Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced the voting results of the Company’s annual and general meeting of shareholders held on January 24, 2023 (the “Meeting”).

Jan 09, 2023 03:00 pm ET

Helix Biopharma Corp. Announces Grant & Cancellation of Stock Options

Toronto, ON - TheNewswire - January 9, 2023 - Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announces that the board of directors has granted 2,300,000 incentive stock options to directors, employees, and consultants of the Company pursuant to its equity compensation plan. Each option has an exercise price of $0.26 for a period of five years from the date of grant with a range of vesting periods.

Dec 14, 2022 05:30 pm ET

Helix BioPharma Corp. Announces Fiscal 2023 First Quarter Results

Toronto, Ontario – Thenewswire – December 14, 2022 – Helix BioPharma Corp. (TSX:HBP), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the fiscal 2023 first quarter results for the three-month period ending October 31, 2022.

Dec 08, 2022 03:00 pm ET

Helix Biopharma Corp. Announces Board & Management Changes

Toronto, ON – TheNewswire - December 8, 2022 - Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced changes in its board of directors (the "Board") and management. The Company is pleased to announce that Mr. Jacek Antas has been appointed as the Company’s CEO to replace Mr. Artur Gabor with immediate effect. Mr. Gabor has resigned as the CEO and a director of the Board of the Company. Mr. Antas has been

Nov 03, 2022 04:00 pm ET

Helix Biopharma Corp. Closes Private Placement of CAD $4.62 Million

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario – TheNewswire – November 3, 2022 - Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announces that it has closed a private placement financing for net proceeds of CAD $4,629,019.86 from the issuance of 25,716,777 common shares at a price of $0.18 per common share. The purchase of common shares by

Nov 01, 2022 05:00 am ET

HELIX BIOPHARMA CORP. Announces Fiscal 2022 Year-End Results

Toronto, Ontario – TheNewswire – November 1, 2022 - Helix BioPharma Corp. (TSX:HBP), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the 2022 fiscal year ended July 31, 2022.

Oct 03, 2022 03:00 pm ET

Helix BioPharma Corp. Appoints Dr. Frank Gary Renshaw as Chief Medical Officer

October 3, 2022 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX:HBP) (OTC:HBPCF) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company that is developing unique therapies in the field of immuno-oncology based on its proprietary technology platform DOS47, is pleased to announce the appointment of Dr. Frank Gary Renshaw, as the Chief Medical Officer.

Sep 01, 2022 03:00 pm ET

Helix Biopharma Corp. Appoints Gabrielle M Siegers as the Head of Research & Development

Toronto, Ontario – TheNewswire – September 1, 2022 – Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company that is developing unique therapies in the field of immuno-oncology based on its proprietary technology platform DOS47, is pleased to announce the appointment of Dr. Gabrielle M Siegers, MA, Ph.D., as the Head of R&D based out of the Company’s lab in Edmonton.

Aug 30, 2022 06:45 am ET

Helix Biopharma Corp. Announces Conclusion of Funding Agreement with Lind Global Macro Fund LP

Toronto, Ontario – TheNewswire – August 30, 2022 – Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company that is developing unique therapies in the field of immuno-oncology based on its proprietary technology platform DOS47, is pleased to announce that it has completed the buyback of the outstanding amount of the convertible security funding agreement (the “Agreement”) with Lind Global Macro Fund, LP, a New York based institutional investment fund managed by The Lind Partners, LLC (together, “Lind”).

Aug 09, 2022 03:00 pm ET

Helix BioPharma Corp. Announces Scientific Collaboration with University Hospital Tuebingen

Toronto, Ontario – TheNewswire – August 9, 2022 – Helix BioPharma Corp. (TSX:HBP) (OTC:HBPCF) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company that is developing unique therapies in the field of immuno-oncology based on its proprietary technology platform DOS47, is pleased to announce that it has entered into a two-year scientific collaboration agreement (“Agreement”) with University Hospital Tuebingen (Germany) to assess the therapeutic response of L-DOS47 in several cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.

Apr 22, 2022 09:45 am ET

Jerzy Wilczewski Announces Acquisition of Common Shares of Helix Biopharma Corp.

VANCOUVER, BC / ACCESSWIRE / April 22, 2022 / Mr. Jerzy Wilczewski announces the acquisition of 7,700,000 common shares ("Common Shares") in the capital of Helix Biopharma Corp. ("Helix" or the "Company") (TSX: HBP) at a price of $0.26 per Common Share by way of non-brokered private placement for an aggregate subscription price of C$2,002,000 (the "Private Placement").

Apr 21, 2022 06:30 pm ET

Helix Biopharma Corp. Closes Private Placement

RICHMOND HILL, ON / ACCESSWIRE / April 21, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announces that it has closed a private placement financing for net proceeds of $2,002,000 from the issuance of 7,700,000 common shares at a price of $0.26 per common share.

Apr 18, 2022 11:00 am ET

Helix Biopharma Corp. Announces Appointment of Permanent CEO and Independent Board Members

RICHMOND HILL, ON / ACCESSWIRE / April 18, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platformDOS47, is pleased to announce that Artur Gabor has been appointed as the Company's Chief Executive Officer with immediate effect.

Apr 13, 2022 05:00 pm ET

Helix Biopharma Corp. Announces Extension of Early Warrant Exercise Incentive Program and Receipt of Private Placement Subscription

RICHMOND, ON / ACCESSWIRE / April 13, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to extend its previously announced Early Warrant Exercise Incentive Program (the "Incentive Program") from April 28, 2022 to May

Apr 07, 2022 12:30 pm ET

Helix Announces Board Resignation

RICHMOND HILL, ON / ACCESSWIRE / April 7, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced the resignation of Dr. Krzysztof Saczek from the Board of Directors with immediate effect.

Mar 22, 2022 06:30 pm ET

Helix Biopharma Corp. Announces Management and Board Changes

RICHMOND HILL, ON / ACCESSWIRE / March 22, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced that Frank Michalargias has notified the Board of Directors of the Company of his intention to resign from the position of Chief Financial Officer, effective no later than May 15, 2022. Mr. Michalargias will be departing the Company to pursue a new employment opportunity.

Mar 16, 2022 06:30 pm ET

Helix Biopharma Corp. Announces Fiscal 2022 Second Quarter Results

RICHMOND, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced fiscal 2022 second quarter results for the period ending January 31, 2022.

Mar 16, 2022 08:00 am ET

Helix Biopharma Corp. Announces Unexpected Passing of Interim CEO and Chairman of the Board

RICHMOND HILL, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company") today announces, with great sadness, the sudden passing of its Interim Chief Executive Officer and Chairman of the Board of Directors (the "Board"), Prof. Dr. S Slawomir Majewski.

Mar 11, 2022 05:38 pm ET

CORRECTION: Helix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise Period

(This release corrects the release that was posted earlier on March 11, 2022 due to the incorrect company logo being added. This release adds the corrected logo)

Mar 11, 2022 05:00 pm ET

Helix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise Period

RICHMOND HILL, ON / ACCESSWIRE / March 11, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announces that it has closed a private placement financing for gross proceeds of $1,001,000 from the issuance of 3,850,000 common share at a price of $0.26 per common share.

Jan 28, 2022 05:00 pm ET

Helix BioPharma Corp. Reports Voting Results and Appointment of New Board Director

RICHMOND HILL, ON / ACCESSWIRE / January 28, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the voting results of the Company's annual and special meeting of shareholders held on January 28, 2022 (the "Meeting"). In aaccordance with section11.3 of National Instrument 51-102 Continuous Disclosure Obligations, and the appointment of Mr. Adam Uszpolewicz to Helix's Board of Directors.

Dec 31, 2021 07:30 am ET

Helix BioPharma Corp. Provides Corporate Update

RICHMOND HILL, ON / ACCESSWIRE / December 31, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to provide a corporate update on initiatives that were undertaken by the Company in 2021.

Dec 15, 2021 05:30 pm ET

Helix Biopharma Corp. Announces Fiscal 2022 First Quarter Results

RICHMOND HILL, ON / ACCESSWIRE / December 15, 2021 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced fiscal 2022 first quarter results for the period ending October 31, 2021.

Dec 13, 2021 06:25 pm ET

Helix BioPharma Corp. Extends Period to Exercise Warrants

RICHMOND HILL, ON / ACCESSWIRE / December 14, 2021 / Helix BioPharma Corp. (TSX:HBP)(FSE:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it is extending the exercise period of a total of 1,520,000 outstanding common share purchase warrants (the "Warrants"), all of which are held by arm's length parties, for a period of two years from their current expiry dates (the "Warrant Extension"). The Warrants were issued pursuant to p

Dec 09, 2021 05:45 pm ET

Helix Biopharma Corp. Announces Fiscal 2021 Year-End Results

RICHMOND HILL, ON / ACCESSWIRE / December 9, 2021 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the 2021 fiscal year ended July 31, 2021.

Nov 30, 2021 08:00 pm ET

Helix BioPharma Corp. Provides Third Bi-Weekly MCTO Status Update

RICHMOND HILL, ON / ACCESSWIRE / November 30, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is providing this bi-weekly update on the status of the management cease trade order granted on November 1, 2021 (the "MCTO") by its principal regulator, the Ontario Securities Commission under National Policy 12-203 Management Cease Trade Orders ("NP 12-203"), following the Company's announcements on October 15,

Nov 15, 2021 06:15 pm ET

Helix BioPharma Corp. Provides Second Bi-Weekly MCTO Status Update

RICHMOND HILL, ON / ACCESSWIRE / November 15, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is providing this bi-weekly update on the status of the management cease trade order granted on November 1, 2021 (the "MCTO") by its principal regulator, the Ontario Securities Commission under National Policy 12-203 Management Cease Trade Orders ("NP 12-203"), following the Company's announcements on October 15,

Nov 01, 2021 07:00 pm ET

Helix BioPharma Corp. Provides Bi-Weekly MCTO Status Update

RICHMOND HILL, ON / ACCESSWIRE / November 1, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is providing this bi-weekly update on the status of the management cease trade order granted on November 1, 2021 (the "MCTO") by its principal regulator, the Ontario Securities Commission under National Policy 12-203 Management Cease Trade Orders ("NP 12-203"), following th

Oct 15, 2021 08:00 pm ET

Helix BioPharma Corp. Announces Delay of Annual Filings

RICHMOND HILL, ON / ACCESSWIRE / October 15, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced today that it anticipates the filing of its annual financial statements, management's discussion and analysis, annual information form and related officer certifications for the financial year ended July 31, 2021 (collectively, the "Annual Filings") will be delayed beyond the required filing deadline und

Sep 20, 2021 05:23 pm ET

Helix BioPharma Corp. Announces Appointment of Interim Chief Executive Officer

RICHMOND HILL, ON / ACCESSWIRE / September 20, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Company's Chairman of the Board, Prof. Dr. Slawomir Majewski, will immediately assume the role of Interim CEO while the Company continues to identify and evaluate candidates.

Aug 19, 2021 08:00 am ET

Helix BioPharma Corp. Announces Appointment of New Director

RICHMOND HILL, ON / ACCESSWIRE / August 19, 2021 / Helix BioPharma Corp. (TSX:HBP) ('Helix' or the 'Company'), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Dr. Krzysztof Saczek has been appointed as a member of the Board of Directors of the Company effective immediately.

Jun 30, 2021 05:00 pm ET

Helix BioPharma Corp. Announces Changes to the Company's Board of Directors and Management

For more information, please contact:Helix BioPharma Corp.9120 Leslie Street, Suite 205Richmond Hill, Ontario, L4B 3J9Tel: 905-841-2300 x 233Frank Michalargias, Chief Financial Officer

Jun 24, 2021 05:00 pm ET

Helix BioPharma Corp. Announces Appointment of New Auditor and Extends Period to Exercise Warrants

RICHMOND HILL, ON / ACCESSWIRE / June 24, 2021 / Helix BioPharma Corp. (TSX:HBP) ('Helix' or the 'Company'), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has appointed Marcum LLP as the Company's new auditor, replacing BDO Canada LLP. The Company has filed a Notice of Change of Auditor in respect of this change under its SEDAR profile at www.sedar.com.

Jun 14, 2021 06:00 pm ET

Helix BioPharma Corp. Announces Fiscal Third Quarter 2021 Results

RICHMOND HILL, ON / ACCESSWIRE / June 14, 2021 / Helix BioPharma Corp. (TSX:HBP), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal third quarter ended April 30, 2021.

May 13, 2021 09:00 am ET

Helix BioPharma Corp. Announces Closing of First Tranche of Institutional Investment for Gross Proceeds of CAD$3.5 million

RICHMOND HILL, ON / ACCESSWIRE / May 13, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has closed the first tranche of the previously announced private placement pursuant to the convertible security funding agreement (the "Agreement") with Lind Global Macro Fund, LP, a New York based institutional investment fund managed by The Lind Partners, LLC (together

May 11, 2021 08:00 am ET

Helix BioPharma Corp. Announces Institutional Investment for Gross Proceeds of up to CAD$10 million

RICHMOND HILL, ON / ACCESSWIRE / May 11, 2021 / Helix BioPharma Corp.(TSX:HBP)("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has entered into a definitive convertible security funding agreement (the "Agreement") with Lind Global Macro Fund, LP, a New York based institutional investment fund managed by The Lind Partners, LLC (together, "Lind"). Under the terms of the Agreement, an initi

Apr 09, 2021 05:00 pm ET

Helix BioPharma Corp. Extends Period to Exercise Warrants

RICHMOND HILL, ON / ACCESSWIRE / April 9, 2021 / Helix BioPharma Corp. (TSX:HBP)(FSE:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to extend the exercise period of a total of 2,837,000 outstanding common share purchase warrants (the "Warrants"), all of which are

Mar 16, 2021 05:00 pm ET

Helix BioPharma Corp. Announces Fiscal Second Quarter 2021 Results

RICHMOND HILL, ON / ACCESSWIRE / March 16, 2021 / Helix BioPharma Corp. (TSX:"HBP"), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal second quarter ended January 31, 2021.

Feb 16, 2021 08:00 am ET

Helix BioPharma Corp. Appoints Dr. Frank Gary Renshaw To Scientific Advisory Board

RICHMOND HILL, ON / ACCESSWIRE / February 16, 2021 / Helix BioPharma Corp. (TSX:HBP), ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced the appointment of Dr. Frank Gary Renshaw to the Company's Scientific Advisory Board.

Jan 28, 2021 05:40 pm ET

Helix Biopharma Corp. Reports Voting Results

RICHMOND HILL, ON / ACCESSWIRE / January 28, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced the voting results of the Company's annual and special meeting of shareholders held on January 28, 2021 (the "Meeting"). In accordance with section 11.3 of National Instrument 51-102 Continuous Disclosure Obligations, th

Jan 13, 2021 03:55 pm ET

Helix Biopharma Corp. Responds to Market Activity

RICHMOND HILL, ON / ACCESSWIRE / January 13, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level of trading volume of its ordinary shares.

Dec 30, 2020 05:00 pm ET

Helix BioPharma Corp. Closes Private Placement

RICHMOND HILL, ON / ACCESSWIRE / December 30, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced it has closed a private placement financing for gross proceeds of $3,000,000.

Dec 22, 2020 05:00 pm ET

Helix BioPharma Corp. Finalizes Polish Subsidiary Divestiture

RICHMOND HILL, ON / ACCESSWIRE / December 22, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has closed the transaction with CAIAC Fund Management AG ("CAIAC") for the Company's remaining holdings in its Polish subsidiary, Helix Immuno-Oncology S.A. ("HIO"), for gross proceeds of PLN 6,700,000 (

Dec 15, 2020 11:50 pm ET

Helix Biopharma Corp. Announces Fiscal 2021 First Quarter Results

RICHMOND HILL, ON / ACCESSWIRE / December 15, 2020 / Helix BioPharma Corp. (TSX:HBP), ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced its fiscal 2021 first quarter results for the period ending October 31, 2020.

Dec 04, 2020 08:30 pm ET

Helix BioPharma Corp. Closes Private Placement

RICHMOND HILL, ON / ACCESSWIRE / December 4, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced it has closed a private placement financing for gross proceeds of $1,100,000.

Nov 09, 2020 05:00 pm ET

Helix BioPharma Corp. Signs Definitive Agreement to Fully Divest Polish Subsidiary

RICHMOND HILL, ON / ACCESSWIRE / November 9, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has signed a definitive share purchase agreement with CAIAC Fund Management AG ("CAIAC"), as designed trustee of HIO Fund (the "Fund"), to purchase Helix's remaining holdings in its Polish subsidiary, Hel

Oct 29, 2020 05:50 pm ET

Helix BioPharma Corp. Announced Fiscal 2020 Year-End Results

RICHMOND HILL, ON / ACCESSWIRE / October 29, 2020 / Helix BioPharma Corp. (TSX:HBP), ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced its financial results for the 2020 fiscal year ended July 31, 2020.

Sep 30, 2020 05:00 pm ET

Helix Biopharma Corp. Provides Polish Subsidiary Divestiture Update

RICHMOND HILL, ON / ACCESSWIRE / September 30, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced an update on the progress regarding the non-binding term sheet the Company received and previous announced on June 26, 2020 to divest the remaining shares it holds in its Polish subsidiary, Helix Immuno-Oncology S.A.

Aug 31, 2020 05:00 pm ET

Helix BioPharma Corp. Provides Polish Subsidiary Divestiture Update

RICHMOND HILL, ON / ACCESSWIRE / August 31, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced an update on the progress regarding the non-binding term sheet the Company received and previous announced on June 26, 2020 to divest the remaining shares it holds in its Polish subsidiary (the "Divestment"

Aug 12, 2020 08:00 am ET

Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration

RICHMOND HILL, ON / ACCESSWIRE / August 12, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), is a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47, today announced that it has extended its collaboration agreement with Moffitt Cancer Center ("Moffitt") for an additional year.

Jul 30, 2020 05:42 pm ET

Helix Biopharma Corp. Announces Fiscal Third Quarter 2020 Results

Helix BioPharma Corp. (TSX: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal third quarter ended April 30, 2020. OVERVIEW The Company...

Jul 27, 2020 08:00 am ET

Helix BioPharma Corp. to Present at Alpha Bronze Virtual Town Hall

NEW YORK, NY / ACCESSWIRE / July 27, 2020 / Alpha Bronze, LLC ("Alpha Bronze"), is pleased to announce that Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, will be presenting at Alpha Bronze Virtual Town Hall on Wednesday, July 29, 2020 at 12:00 PM EDT.

Jul 13, 2020 07:30 am ET

Helix BioPharma Corp. Provides Update On The Timing Of Filing Of Third Quarter Results

Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announces that, further to its news release dated June 11, 2020, it...

Jun 26, 2020 07:30 am ET

Helix BioPharma Corp. to divest remaining ownership of Polish subsidiary

Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced that it has...

Jun 22, 2020 02:19 pm ET

Proactive Virtual Event Showcases Four Rising Stars of the Life Sciences Industry

Proactive, the digital financial news organization, will be showcasing four rising stars of the life sciences industry with its first North American virtual investor conference. The event will feature live webcast presentations from companies...

Jun 22, 2020 07:30 am ET

Helix BioPharma Corp. to Present at Proactive One2One Virtual Investor Forum

Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it will be presenting at Proactive One2One Virtual...

Jun 11, 2020 05:15 pm ET

Helix BioPharma Corp. Provides Update On The Timing Of Filing Of Third Quarter Results

Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announces that it intends to rely on exemptions granted in Ontario...

May 14, 2020 07:30 am ET

Helix BioPharma Corp. L-DOS47 Phase I Lung Cancer Trial Data to be released at ASCO 2020

Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that topline data of the recently completed L-DOS47 dose escalation...

Apr 02, 2020 07:30 am ET

Helix BioPharma Corp. Provides Corporate Update

Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today provides a corporate update. COVID-19 As countries across the globe...

Mar 16, 2020 07:51 pm ET

HELIX BIOPHARMA CORP. ANNOUNCES FISCAL SECOND QUARTER 2020 RESULTS

Helix BioPharma Corp. (TSX: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal second quarter ended January 31, 2020. OVERVIEW The...

Mar 12, 2020 05:05 pm ET

Helix BioPharma Corp. Closes $6.0 Million Private Placement

Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing of 5,042,016...

Feb 14, 2020 07:30 am ET

Helix BioPharma Corp. to Present at the Noble Capital Markets’ Sixteenth Annual Investor Conference

Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Dr. Heman Chao, Helix’s Chief Executive Officer, will...

Jan 13, 2020 05:32 pm ET

Helix BioPharma Corp. Closes $3.0 Million Private Placement

Jan 08, 2020 10:58 am ET

Helix BioPharma Corp. to Present at the Biotech Showcase Conference in San Francisco

Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has been selected to present at the Biotech Showcase...

Dec 13, 2019 07:35 am ET

Helix BioPharma Corp. Announces Fiscal First Quarter 2020 Results

Helix BioPharma Corp. (TSX, FSE: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2020 ending October 31, 2019....

Dec 11, 2019 06:09 pm ET

Helix BioPharma Corp. Commences L-DOS47 Phase lb/ll Pancreatic Cancer Clinical Study

Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the start of enrollment and screening in the...

Dec 06, 2019 07:12 pm ET

Helix BioPharma Corp. Reports Voting Results

Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the voting results of the Company’s annual and special...

Oct 25, 2019 07:33 am ET

Helix BioPharma Corp. Announces Fiscal 2019 Year-End Results

Helix BioPharma Corp. (TSX: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2019. FINANCIAL REVIEW The Company recorded a...

Oct 10, 2019 05:05 pm ET

Helix BioPharma Corp. Board Changes

Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced a change in the Company’s Board of Directors. The Board has...

Sep 03, 2019 07:30 am ET

Helix BioPharma Corp. and Moffit Cancer Centre to Present at World Molecular Imaging Congress

Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that they, together with Moffitt Cancer Center...

Aug 21, 2019 05:05 pm ET

Helix BioPharma Corp. Closes $7.0 Million Private Placement

Aug 07, 2019 07:06 pm ET

Helix Biopharma Corp. Receives U.S. FDA Approval for Phase Ib/II Pancreatic Trial

Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced that it has received approval from the U.S. Food and Drug...

Jul 24, 2019 05:05 pm ET

Helix Biopharma Corp. to Present at RHK Capital Conference in New York

Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that it will be presenting at the RHK Capital 2019 Disruptive...

Jul 09, 2019 07:30 am ET

Helix BioPharma Corp. Submits L-DOS47 IND Application With U.S. FDA for Pancreatic Cancer

Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the submission of an Investigational New Drug (“IND”)...

Jun 11, 2019 07:33 am ET

Helix BioPharma Corp. Announces Fiscal Third Quarter 2019 Results

Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces its financial results for its fiscal third quarter...

May 30, 2019 05:48 pm ET

Helix BioPharma Corp. Initiates OTCQB Application and Hires U.S. Investor Relations Firm

May 29, 2019 06:22 pm ET

Helix BioPharma Corp. Closes Private Placement

May 01, 2019 08:08 am ET

L-DOS47 Phase II Randomized Study Advances to Second Cohort

Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, has announced that the Trial Steering Committee ("TSC") reviewed safety data...

Apr 29, 2019 06:54 pm ET

Helix BioPharma Corp. Closes Second Tranche of Private Placement

Apr 18, 2019 05:05 pm ET

Helix BioPharma Corp. Closes First Tranche of Private Placement

Apr 17, 2019 05:19 pm ET

Helix BioPharma Corp. Retains U.S. Legal and Capital Firms to Advise on U.S. Listing

Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has retained Sheppard Mullin, Richter and Hampton LLC...

Apr 15, 2019 10:14 pm ET

Helix BioPharma Corp. Reports Voting Results

Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the voting results of the Company’s annual and special...

Mar 18, 2019 07:36 am ET

Helix BioPharma Corp. Announces Fiscal Second Quarter 2019 Results

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces its financial results for its fiscal...

Mar 15, 2019 05:30 pm ET

Helix BioPharma Corp. Closes Private Placement, Extends Period to Exercise Warrants and Provides Corporate Update

Helix BioPharma Corp. (TSX, FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has closed a private placement financing for...

Mar 07, 2019 05:30 pm ET

Helix BioPharma Corp.: First Patient Dosed in a Phase II Randomized Study of L-DOS47 With Vinorelbine and Cisplatin

Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce the first patient has been successfully...

Feb 27, 2019 05:30 pm ET

Helix BioPharma Corp. and Moffitt Cancer Center to Present at the AACR Annual Meeting 2019 in Atlanta

Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that together with the Moffitt Cancer...

Feb 11, 2019 07:30 am ET

Helix BioPharma Corp. Provides Clinical Development and Strategic Corporate Update

Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer today provides an update on the Company’s strategic plans....

Feb 08, 2019 07:57 am ET

Helix BioPharma Corp. Board Changes

Helix BioPharma Corp. (TSX: HBP) (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced a change in the Company’s Board of Directors....

Jan 28, 2019 07:30 am ET

Helix BioPharma Corp. Extends Annual Meeting Date

Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received consent from the Toronto Stock Exchange to extend...

Dec 28, 2018 05:05 pm ET

Helix BioPharma Corp. Closes Final Tranche of Private Placement

Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a final tranche of a private placement...

Dec 21, 2018 05:06 pm ET

Helix BioPharma Corp. Closes Third Tranche of Private Placement

Dec 20, 2018 05:05 pm ET

Helix BioPharma Corp. Closes Second Tranche of Private Placement

Dec 14, 2018 05:34 pm ET

Helix BioPharma Corp. Announces Fiscal First Quarter 2019 Results

Dec 06, 2018 05:05 pm ET

Helix Biopharma Corp. Closes First Tranche of Private Placement

Nov 13, 2018 05:05 pm ET

Helix BioPharma Corp. Provides Strategic Update on L-DOS47 Clinical Program

Helix BioPharma Corp. (TSX, FSE: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, provides a strategic update of its L-DOS47 clinical program. Helix’s L-DOS47 strategic development plan has...

Nov 01, 2018 07:30 am ET

Helix BioPharma Corp. to initiate new L-DOS47 clinical program in pancreatic cancer

Oct 30, 2018 05:05 pm ET

Helix BioPharma Corp. Closes Private Placement

Oct 26, 2018 05:25 pm ET

Helix BioPharma Corp. Announces Fiscal 2018 Year-End Results

Helix BioPharma Corp. (TSX, FSE: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2018. FINANCIAL REVIEW The...

Oct 16, 2018 06:03 pm ET

Helix BioPharma Corp. Extends Period to Exercise Warrants

Helix BioPharma Corp. (TSX, FSE: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received conditional approval from the...

Oct 10, 2018 07:30 am ET

Helix BioPharma Corp. and Moffitt Cancer Center extend collaboration on immunotherapy, including study of L-DOS47 with PD-1/PD-L1 inhibitors

Sep 13, 2018 07:30 am ET

Helix BioPharma Corp. Initiates Enrollment of the Second Last Cohort in U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47

Sep 12, 2018 07:30 am ET

Helix BioPharma Corp. collaborator ProMab Biotechnologies Publishes Paper on Multiple Myeloma CAR-T

Helix BioPharma Corp. (TSX:HBP), (FSE:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that its collaborator ProMab Biotechnologies, Inc....

Sep 10, 2018 05:05 pm ET

Helix BioPharma Corp. Closes Private Placement

Helix BioPharma Corp. (TSX:HBP)(FSE:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross...

Sep 04, 2018 05:05 pm ET

Helix BioPharma Corp. collaborator ProMab Biotechnologies to present at the CAR-TCR Summit 2018 in Boston

Aug 08, 2018 05:05 pm ET

Helix BioPharma Corp. Closes Private Placement

Jul 25, 2018 05:05 pm ET

Helix BioPharma Corp. Completes Fourth Dosing Cohort and Initiates Enrollment of the Next Cohort in U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47

Helix BioPharma Corp. (TSX:HBP) (FSE:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Safety Review Committee ("SRC") reviewed...

Jul 09, 2018 05:05 pm ET

Helix BioPharma Corp. Closes Private Placement

Helix BioPharma Corp. (TSX:HBP) (FSE:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross...

Jun 12, 2018 05:16 pm ET

Helix BioPharma Corp. Announces Fiscal Third Quarter 2018 Results

Helix BioPharma Corp. (TSX:HBP) (FRANKFURT:HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces its financial results for its fiscal...

Jun 07, 2018 05:14 pm ET

Helix BioPharma Corp. Closes Private Placement

Helix BioPharma Corp. (TSX:HBP) FSE:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross...

May 30, 2018 05:05 pm ET

Helix BioPharma Corp. Completes Third Dosing Cohort and Initiates Enrollment of the Next Cohort in U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47

Apr 30, 2018 05:05 pm ET

Helix BioPharma Corp. Closes Private Placement

RICHMOND HILL, Ontario, April 30, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP) (FSE:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a...

Apr 10, 2018 07:30 am ET

Helix BioPharma Corp. Announces Regulatory Approval to Dose Patients in a Phase II Randomized Study of L-DOS47 With Vinorelbine and Cisplatin

RICHMOND HILL, Ontario, April 10, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP) (FRANKFURT:HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that all...

Mar 22, 2018 07:30 am ET

Helix BioPharma Corp Welcomes Drs. Daniel Von Hoff, Kazimierz Roszkowski-Sliz and Robert Gillies to Its Scientific and Strategic Advisory Board

RICHMOND HILL, Ontario, March 22, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP) (FSE:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the formation of the...

Mar 21, 2018 07:30 am ET

Helix BioPharma Corp. Signs Collaboration Agreement With ProMab Biotechnologies to Co-Develop CAR-T for Hematological Malignancies

RICHMOND HILL, Ontario, March 21, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP), (FSE:HBP) (“Helix” or the “Company”), a immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the completion of the...

Mar 19, 2018 08:19 pm ET

Helix BioPharma Corp. Announces Fiscal Second Quarter 2018 Results

RICHMOND HILL, Ontario, March 19, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP) (FRANKFURT:HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces its financial results...

Feb 23, 2018 07:30 am ET

L-DOS47 US Phase I Study Presentation at the IASLC 18th Annual Target Therapies of Lung Cancer Meeting

RICHMOND HILL, Ontario, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP) (FRANKFURT:HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce...

Feb 22, 2018 05:00 pm ET

Helix BioPharma Corp. Appoints Deloitte as Strategic Advisor to Explore Partnering and Licensing Opportunities

RICHMOND HILL, Ontario, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP) (FRANKFURT:HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the...

Feb 06, 2018 07:30 am ET

Helix Biopharma Corp. and Helix Immuno-Oncology to Present at the AACR Annual Meeting 2018 in Chicago

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that together with its wholly-owned subsidiary Helix Immuno-Oncology, it will present a poster entitled: Targeting Urease to Human VEGFR2 Elicits Antitumor Activity in Triple-Negative Breast Cancer Models at the American Association for Cancer Research ("AACR") Annual Meeting 2018 which is taking place on April 14 - 18, 2018 at McCormick

Feb 06, 2018 07:28 am ET

Helix Biopharma Corp. and Helix Immuno-Oncology to Present at the AACR Annual Meeting 2018 in Chicago

Jan 05, 2018 05:33 pm ET

Helix Biopharma Corp. to Present at the Biotech Showcase Conference

Jan 05, 2018 05:33 pm ET

Helix Biopharma Corp. to Present at the Biotech Showcase Conference

Helix BioPharma Corp. (TSX: HBP)(FRANKFURT: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has been selected to present at the Biotech Showcase Conference on Monday, January 8, 2018 at 4:30pm (PT) at Hilton San Francisco Union Square.

Jan 04, 2018 05:43 pm ET

Helix Biopharma Corp. Signs Binding Letter of Intent for Development of New CAR-T Technologies

Helix BioPharma Corp. (TSX: HBP)(FRANKFURT: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the finalization of a collaborative binding letter of intent ("LOI") with ProMab Biotechnologies, Inc. ("ProMab") to develop chimeric antigen receptor T-cell therapy ("CAR-T") for hematological malignances and solid tumours.

Jan 04, 2018 05:43 pm ET

Helix Biopharma Corp. Signs Binding Letter of Intent for Development of New CAR-T Technologies

Dec 22, 2017 05:05 pm ET

Helix BioPharma Corp. Closes Private Placement

Dec 22, 2017 05:03 pm ET

Helix BioPharma Corp. Closes Private Placement

Dec 13, 2017 05:28 pm ET

Helix BioPharma Corp. Announces Fiscal First Quarter 2018 Results

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2018 ending October 31, 2017.

Dec 13, 2017 05:27 pm ET

Helix BioPharma Corp. Announces Fiscal First Quarter 2018 Results

Helix BioPharma Corp. (TSX:HBP) (FRANKFURT:HBP), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2018 ending October 31, 2017....

Dec 12, 2017 05:24 pm ET

Helix BioPharma Corp. Announces Voting Results From Annual and Special Meeting of Shareholders

Helix BioPharma Corp. (TSX:HPB)(FRANKFURT:HBP) ("Helix"), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announced today the results of matters voted on at its annual and special meeting of...

Dec 12, 2017 05:24 pm ET

Helix BioPharma Corp. Announces Voting Results From Annual and Special Meeting of Shareholders

Helix BioPharma Corp. (TSX: HPB)(FRANKFURT: HBP) ("Helix"), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announced today the results of matters voted on at its annual and special meeting of shareholders held on December 12, 2017 (the "Meeting").

Dec 01, 2017 05:05 pm ET

Helix BioPharma Corp. Announces Management Change

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced Steve Demas, its Chief Operating Officer, has resigned due to personal reasons. "I want to thank Steve on behalf of Helix for his significant contribution to the Company," said Heman Chao, Chief Executive Officer. "I wish him the best in his future endeavors".

Dec 01, 2017 05:03 pm ET

Helix BioPharma Corp. Announces Management Change

Oct 27, 2017 06:11 pm ET

Helix BioPharma Corp. Announces Fiscal 2017 Year-End Results and Provides Research and Development Program Update

Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2017 and an update on the Company's...

Oct 27, 2017 06:11 pm ET

Helix BioPharma Corp. Announces Fiscal 2017 Year-End Results and Provides Research and Development Program Update

Helix BioPharma Corp. (TSX: HBP)(FRANKFURT: HBP), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2017 and an update on the Company's research and development programs.

Oct 19, 2017 04:48 pm ET

Helix BioPharma Corp. Closes Private Placement

Oct 19, 2017 04:48 pm ET

Helix BioPharma Corp. Closes Private Placement

Sep 27, 2017 05:08 pm ET

Helix BioPharma Corp. announces FDA approval to Accelerate Dose Escalation for U.S. Phase I Clinical Study

Sep 27, 2017 05:08 pm ET

Helix BioPharma Corp. announces FDA approval to Accelerate Dose Escalation for U.S. Phase I Clinical Study

Helix BioPharma Corp. (TSX: HBP)(FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the U.S. Food and Drug Administration ("FDA") has approved an amendment to their U.S. Phase I study, protocol LDOS001, that will accelerate the dose escalation phase of the study.

Aug 31, 2017 04:35 pm ET

Helix Biopharma Corp. Closes Private Placement

Aug 31, 2017 04:34 pm ET

Helix Biopharma Corp. Closes Private Placement

Aug 22, 2017 07:30 am ET

Helix Announces Peer-Review Publication of V-DOS47 in Frontiers in Immunology Journal

Helix BioPharma Corp. (TSX: HBP)(FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the publication of a peered-reviewed V-DOS47 manuscript in "Frontiers in Immunology" journal. V-DOS47 is Helix's second DOS47 development candidate following L-DOS47, which is currently in clinical testing for the treatment of non-small cell lung cancer.

Aug 22, 2017 07:28 am ET

Helix Announces Peer-Review Publication of V-DOS47 in Frontiers in Immunology Journal

Jul 31, 2017 04:33 pm ET

Helix Biopharma Corp. to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

Helix BioPharma Corp. (TSX: HBP)(FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that the Company's poster entitled: "Immune checkpoint modulation by urease-mediated alkalization", has been accepted for presentation in the "Checkpoint Blockade Therapy" session at the Third International Cancer lmmunotherapy Conference. The conference is being held in Mainz Germany on September 6th through to the 9th, 2017 at the

Jul 31, 2017 04:31 pm ET

Helix Biopharma Corp. to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

Jul 25, 2017 04:30 pm ET

Helix BioPharma Corp. Initiates Enrollment in the Third Dosing Cohort of U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47

Helix BioPharma Corp. (TSX: HBP)(FRANKFURT: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening in the third dosing cohort of its ongoing U.S. study of L-DOS47 in combination treatment with pemetrexed/carboplatin ("LDOS001").

Jul 25, 2017 04:28 pm ET

Helix BioPharma Corp. Initiates Enrollment in the Third Dosing Cohort of U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47

Jul 18, 2017 05:02 pm ET

Helix BioPharma Corp. and Moffitt Cancer Center to investigate L-DOS47 and checkpoint blockade

Helix BioPharma Corp. (TSX: HBP)(FRANKFURT: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has entered into a collaboration agreement with Moffitt Cancer Center to perform basic research studies to further investigate the pharmacodynamics of L-DOS47 and determine the potential benefits of combining L-DOS47 with immune checkpoint inhibitors.

Jul 18, 2017 05:01 pm ET

Helix BioPharma Corp. and Moffitt Cancer Center to investigate L-DOS47 and checkpoint blockade

Jul 17, 2017 07:00 am ET

Helix BioPharma Corp. Director Resigns

Helix BioPharma Corp. (TSX: HBP)(FRANKFURT: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Board has accepted Mr. Albert Beraldo's resignation as director of the Company and Audit Committee Chair, effective July 14, 2017. Mr. Beraldo has conveyed to the Board that his other commitments have become too great for him to be able to fulfill the requirements of his position on the Board and determined it best for him to step down and make room for someone

Jul 17, 2017 06:58 am ET

Helix BioPharma Corp. Director Resigns

Jul 11, 2017 07:00 am ET

Helix BioPharma Corp. Announces Collaboration with Moffitt Cancer Center

Helix BioPharma Corp. (TSX: HBP)(FRANKFURT: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has entered into a collaboration agreement with Moffitt Cancer Center to extract radiomics data using their proprietary HealthMyne platform from CT scans of late stage lung cancer patients treated with L-DOS47.

Jul 11, 2017 06:58 am ET

Helix BioPharma Corp. Announces Collaboration with Moffitt Cancer Center

Jun 13, 2017 05:50 pm ET

Helix BioPharma Corp. Announces Fiscal Third Quarter 2017 Results

Jun 13, 2017 05:49 pm ET

Helix BioPharma Corp. Announces Fiscal Third Quarter 2017 Results

Jun 07, 2017 07:19 pm ET

Helix BioPharma Corp. Closes Private Placement

Jun 07, 2017 07:19 pm ET

Helix BioPharma Corp. Closes Private Placement

May 30, 2017 07:30 am ET

Helix BioPharma Corp. to Present at 3rd Annual Immuno-Oncology BD&L and Investment Forum

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that company Chief Executive Officer and Chief Science Officer, Heman Chao, will be presenting at the upcoming 3rd Annual Immuno-oncology BD&L and Investment Forum ("IOBD&L") taking place on June 2nd, 2017 at the Hyatt Chicago Magnificent Mile Hotel.

Apr 27, 2017 04:32 pm ET

Helix BioPharma Corp. Closes Private Placement

Apr 03, 2017 07:45 am ET

Helix BioPharma Corp. to Present CAR-T at AACR Annual Meeting 2017 in Washington, D.C.

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that its poster entitled: CAR-T cell harboring a camelid single domain antibody as a targeting agent to kill tumours expressing VEGFR2 has been accepted for presentation at the AACR Annual Meeting 2017 taking place on April 1 - 5, 2017 at the Walter E. Washington Convention Center Washington, D.C., USA.

Mar 21, 2017 08:00 am ET

L-DOS47 Phase I Study Results To Be Presented at the 9th International Conference of Contemporary Oncology

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that results from the Phase I L-DOS47 study will be presented at the upcoming 9th International Conference of Contemporary Oncology meeting in Poznan, Poland from the 22nd to the 24th of March, 2017. The leading theme of the conference is genome-based precision oncology -- direct targeting and immune-targeting of cancer.

Mar 17, 2017 07:50 am ET

Helix BioPharma Corp. Announces Fiscal Second Quarter 2017 Results and Closing of Private Placement

Mar 17, 2017 07:50 am ET

Helix BioPharma Corp. Announces Fiscal Second Quarter 2017 Results and Closing of Private Placement

Mar 07, 2017 07:45 am ET

Helix BioPharma Corp. Announces Strategic Management Changes

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that Dr. Sven Rohmann, CEO and Chairman of the Company, will be stepping down from his position as Chief Executive Officer of Helix BioPharma Corp., effective March 31, 2017, in order to focus his activities on chairing the board and to act as strategic advisor to the Company. Stepping into the role of Chief Executive Officer will be Dr. Heman Chao, effective March 31, 2017. Dr. Chao

Feb 27, 2017 07:30 am ET

Helix BioPharma Corp. Announces Licence for Worldwide Right to Anti-CEACAM6 Antibody From the Government of Canada

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that it has completed a licence agreement with the National Research Council of Canada ("NRC") for the worldwide right to anti-CEACAM6 antibody 2A3 for oncology applications.

Feb 22, 2017 07:30 am ET

30Mil CAD$ Investment in European Centre of Cancer Immunotherapy

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that Helix Immuno-Oncology ("HIO") has signed a non-binding letter of intent with KEN Poland Limited Liability Partnership ("KEN POLAND") in support of the European Centre for Cancer Immunotherapy ("ECCI").

Feb 13, 2017 07:45 am ET

Helix BioPharma Corp. Conference Attendance 2017

Feb 02, 2017 07:45 am ET

Helix BioPharma Corp. to Present at the BIO CEO & Investor Conference in New York

Jan 23, 2017 07:45 am ET

Helix BioPharma Corp. Announces CAR-T Poster Presentation at AACR Annual Meeting 2017 in Washington, DC

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that its poster entitled: CAR-T cell harboring a camelid single domain antibody as a targeting agent to kill tumours expressing VEGFR2 has been accepted for presentation at the AACR Annual Meeting 2017 taking place on April 1 - 5, 2017 at the Walter E. Washington Convention Center Washington, D.C., USA.

Jan 17, 2017 05:05 pm ET

Helix BioPharma Corp. Announces Voting Results from Its Annual and Special Meeting of Shareholders

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced today the results of matters voted on at its annual and special meeting of shareholders held on January 17, 2017 (the "Meeting").

Jan 17, 2017 05:03 pm ET

Helix BioPharma Corp. Announces Voting Results from Its Annual and Special Meeting of Shareholders

Helix BioPharma Corp. (TSX:HBP) (FRANKFURT:HBP) ("Helix"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced today the results of matters voted on at its annual and...

Dec 30, 2016 07:30 am ET

Helix BioPharma Corp. Announces Additional Private Placement Closing

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has completed an additional closing of its previously announced private placement. On December 28, 2016, Helix issued 1,313,000 units under the private placement for gross proceeds of approximately CAD1.58 million. On December 29, 2016, Helix issued 207,000 units under the private placement for gross proceeds of approximately CAD0.24 million. The aggregate gross proceeds raised by the

Dec 29, 2016 08:15 am ET

Helix BioPharma Corp. Closes Private Placement

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has received private placement subscription agreements for units totalling aggregate gross proceeds of approximately CAD1.82 million and had closed on CAD1.58 million.

Dec 23, 2016 07:45 am ET

Helix BioPharma Corp. Successfully Out-Licenses Late Stage Biphasix Technology

Helix BioPharma Corp. ("Helix" or the "Company") (TSX: HBP) (FRANKFURT: HBP), a clinical-stage, immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces today it has signed an exclusive out-license agreement with Xisle Pharma Ventures Trust ("Xisle") for the Company's late-stage, Biphasix™ technology platform, including the lead product candidate, interferon alpha. Xisle will be responsible for the continued clinical development and subsequent commercialization of the product for the treatment of HPV-induced, low-grade, cervical

Dec 22, 2016 07:45 am ET

Helix BioPharma Corp. Announces the Signing of a Non-Binding Letter of Intent With ProMab Biotechnologies to Develop Cell Based Therapies

Dec 13, 2016 07:46 pm ET

Helix BioPharma Corp. Announces Fiscal First Quarter 2017 Results

Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the quarter ended October 31, 2016. HIGHLIGHTS...

Dec 13, 2016 07:46 pm ET

Helix BioPharma Corp. Announces Fiscal First Quarter 2017 Results

Helix BioPharma Corp. (TSX: HBP)(FRANKFURT: HBP), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the quarter ended October 31, 2016.

Dec 09, 2016 08:10 pm ET

Helix BioPharma Corp. to Present at the Biotech Showcase Conference During the Annual JP Morgan Week in San Franscisco

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, intends to meet a selection of Big Pharma and Big Biotech companies during the Annual JP Morgan Conference week in San Francisco during January 9-12, 2017.

Dec 06, 2016 08:30 am ET

Helix BioPharma Corp. Presents Topline L-DOS47 Results at the 17th IASCLC World Conference on Lung Cancer

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announce that it presented topline data from its phase I/II dose escalation study of immunoconjugate L-DOS47 as a monotherapy in non-squamous non-small cell lung cancer patients at the 17th IASCLC World Conference on Lung Cancer ("WCLC") held in Vienna, Austria.

Nov 30, 2016 07:30 am ET

Helix BioPharma Corp. Accelerates Escalation of L-DOS47 Dosing in the U.S. Phase I Study

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that after reviewing safety data from the Phase I/II study of L-DOS47 in non-squamous non-small cell lung cancer (LDOS002), the U.S. Food and Drug Administration ("FDA") has accepted an accelerated escalation scheme for L-DOS47 dosing in the U.S. Phase I study (LDOS001) up to 12µg/kg in combination with pemetrexed/carboplatin.

Nov 17, 2016 08:00 am ET

Helix BioPharma Corp. Announces Poster Presentation of L-DOS47 at the World Conference on Lung Cancer

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that the Company's poster entitled: Phase I/II dose escalation study of immunoconjugate L-DOS47 as a monotherapy in non-squamous non-small cell lung cancer patients has been selected for poster presentation at the 17th World Conference on Lung Cancer ("WCLC") held in Vienna, Austria, December 4-7, 2016. A copy of the poster will be made available on the Company's website. The abstract will be

Oct 31, 2016 07:36 pm ET

Helix BioPharma Corp. Announces Fiscal 2016 Results

Oct 27, 2016 07:30 am ET

Helix BioPharma Corp. Presents at National Investment Banking Association

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Company's Chief Executive Officer, Dr. Sven Rohmann, will present a corporate overview at the National Investment Banking Association ("NIBA") conference on Thursday October 27, 2016 at 10:45am (PT) in the Grand Ballroom, at the Balboa Bay Resort, Newport Beach, CA.

Oct 19, 2016 06:42 pm ET

Helix BioPharma Corp. Announces CAR-T Poster Presentation at the AACR Conference on Tumor Immunology and Immunotherapy

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that its poster entitled: CAR-T cells harboring camelid single domain antibody as targeting agent to CEACAM6 antigen in pancreatic cancer will be presented on Friday, October 21, 2016 during the AACR Conference on Tumor Immunology and Immunotherapy which is taking place on October 20th through to the 23rd, 2016 at the Boston Marriott Copley Place in Boston, Massachusetts.

Oct 06, 2016 06:43 pm ET

Helix BioPharma Corp. to Present at Upcoming Bio Investor Forum in San Francisco

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Company's Chief Executive Officer, Dr. Sven Rohmann, will present a corporate overview at the Bio Investor Forum on Wednesday, October 19th, at 10:00 AM (Pacific) in conference room Elizabethan B at the Westin St. Francis Hotel, San Francisco, CA.

Sep 09, 2016 07:45 am ET

Helix Biopharma Corp. to Present at Precision Lung Cancer World R&D Summit

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that Dr. Heman Chao, Helix's CSO, will be presenting: Therapeutic Strategy Against Tumor Acidity Induced Immune-Suppression: L-DOS47 a Clinical Candidate for Lung Cancer at the Precision Lung Cancer World R&D Summit being held on September 13th and 14th, 2016 at the Royal Sonesta Boston hotel in Boston, Massachusetts.

Sep 07, 2016 07:45 am ET

Helix BioPharma Corp. Announces New Director Appointment

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announces the appointment of Dr. Theordore J. Witek, Jr. to the board of directors of Helix.

Sep 01, 2016 07:30 am ET

Helix BioPharma Corp. Announces CAR-T Poster Presentation at the AACR Conference

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that the Company's poster entitled: CAR-T Cells Harboring Camelid Single Domain Antibody as Targeting Agent to CEACAM6 Antigen in Pancreatic Cancer has been accepted for presentation at the AACR Conference on Tumor Immunology and Immunotherapy taking place on October 20th through to the 23rd, 2016 at the Boston Marriott Copley Place in Boston, Massachusetts. A copy of the

Aug 19, 2016 07:30 am ET

Helix BioPharma Corp. Closes CAD1.0 Million Private Placement

Jul 29, 2016 04:01 pm ET

Helix BioPharma Corp. Closes CAD1.8 Million Private Placement

Jul 26, 2016 07:15 am ET

AACR Approves Helix BioPharma Corp's Poster for Presentation at the International Cancer Immunotherapy Conference

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that the Company's poster entitled: Urease-mediated alkalization of tumor microenvironment and its effects on T cell proliferation, cytokine release and PD-1/PD-L1 interactions, has been accepted for presentation at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival. The conference is being held in New York City

Jul 21, 2016 05:52 pm ET

Helix BioPharma Corp. Subsidiary, Helix Polska Sp. z o.o., Finalizes Grant Funding With the Polish National Center for Research and Development

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that its wholly owned subsidiary, Helix Polska Sp. z o.o. ("Helix Polska" or "Subsidiary") has finalized the Grant Funding Agreement ("Agreement") with the Polish National Centre for Research and Development ("PNCRD") to develop V-DOS47 in breast cancer up to and including a phase I/IIa clinical trial.

Jul 18, 2016 04:10 pm ET

Helix BioPharma Corp. Announces Agreement in Principle With National Research Council of Canada to Collaborate on Various Immuno-Oncology Initiatives

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced that an Agreement in Principle ("Agreement") has been reached with the National Research Council of Canada ("NRC") to collaborate on various immuno-oncology initiatives.

Ad blocking detected

Helix BioPharma Corp. (T:HBP)

Business Focus: Biotechnology & Medical Research (NEC)